At the beginning of August 2019, GSK received approval from the EMA for two new dosage forms of mepolizumab: The IL-5 antibody can now also be administered as a pen and a pre-filled syringe. It is thus the only fixed-dose, four-weekly anti-IL-5 biologic available for treatment in severe eosinophilic asthma, even for patient self-injection outside the office.